Bristol-Myers to file for OTC sale of its Pravachol statin

12/13/2004 | Wall Street Journal, The

Bristol-Myers Squibb has taken official action to get FDA approval to sell its cholesterol-lowering Pravachol over the counter, possibly paving the way for OTC versions of other statins. Bristol-Myers faces the loss of its patent on Pravachol in just over a year and OTC sales are seen as opening a new market for the drugs. An FDA advisory panel plans to meet in mid-January on a similar request by Merck for Mevacor.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Teaching Associate (Hospitality Management)
University of Illinois at Urbana-Champaign
Urbana, IL
Director, Global Regulatory Affairs
Rodan and Fields, LLC
San Francisco, CA
Senior Compliance Analyst
ACell, Inc.
Columbia, MD
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA